Graphite Bio doses first subject in Phase I/II sickle cell disease trial
The trial is presently enrolling subjects with sickle cell disease at various sites in the US.
Hematological Disorders
Latest in
Hematological Disorders
Pipeline Moves: Phase II gout trial termination slashes advancement prospects
We also review assets in allergic rhinitis, anorexia, paroxysmal nocturnal haemoglobinuria, and polyomavirus infections.
By
Ionis reports positive Phase IIb data of fesomersen for thrombosis
In the trial, fesomersen offered a substantial and statistically significant decline in activity levels of Factor XI.
Foghorn’s Phase I AML/MDS trial on FDA partial clinical hold due to subject death
No new subjects will be enrolled in the trial until the FDA lifts the partial clinical hold.
AbbVie reports positive data from Phase II myelofibrosis therapy trial
The trial assessed the efficacy and tolerability of navitoclax alone or with ruxolitinib for myelofibrosis treatment.
Pipeline Moves: Terminations of fatty liver, blood cancer, ophthalmology clinical trials cause further study chances to nosedive
Bristol Myers Squibb, GT Biopharma, and Gemini Therapeutics terminate early-phase trials of their respective assets.
By
PhaseBio reports positive data from Phase IIb antibody trial in uncontrolled bleeding
Findings showed that bentracimab treatment substantially restored platelet function within five minutes of dosing.
Curis’ oral cancer therapy trial receives FDA partial clinical hold
The latest development comes after the company reported the death of a patient with R/R AML.